SpringWorks Therapeutics (SWTX) Announces $225 Million Private Placement Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
SpringWorks Therapeutics Inc. (SWTX) to Resume Trading at 10:25 a.m.
September 7, 2022 10:04 AM EDTSpringWorks Therapeutics Inc. (NASDAQ: SWTX) to Resume Trading at 10:25 a.m.
... MoreSpringWorks Therapeutics (SWTX) Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
September 7, 2022 9:55 AM EDTSpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (LSE/NYSE: GSK) for nirogacestat, SpringWorks investigational oral gamma secretase inhibitor, in combination with Blenrep (belantamab mafodotin-blmf), GSKs antibody-drug conjugate targeting B-cell maturation antigen (BCMA).
Under the terms of the expanded agreement, SpringWorks will receive a $75 million equity investment from GSK, with shares of common... More
